Last updated: February 23, 2026
What is NDC 69238-1731?
NDC 69238-1731 corresponds to Bimzelx (bimekizumab), an interleukin-17A and IL-17F inhibitor approved for treatment of moderate-to-severe plaque psoriasis in adults. Bimzelx was approved by the FDA in December 2021. It targets cytokines involved in inflammatory pathways, positioning it within the biologics segment.
Market Overview
Indications and Patient Population
- Primary indication: Plaque psoriasis
- Estimated patient base in the U.S.: 2.5 million adults with moderate-to-severe plaque psoriasis (IMS Health, 2022)
- Expansion potential: Eczema, psoriatic arthritis (under investigation)
Competitive Landscape
Key competitors include:
| Drug |
Class |
Approval Year |
Annual Cost (approx.) |
Market Share (2022) |
| Cosentyx (secukinumab) |
IL-17A inhibitor |
2015 |
$56,000 |
35% |
| Humira (adalimumab) |
TNF inhibitor |
2003 |
$70,000 |
30% |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
2009 |
$60,000 |
15% |
| Skyrizi (risankizumab) |
IL-23 inhibitor |
2019 |
$65,000 |
6% |
Bimzelx entered a crowded biologics market but offers a dual IL-17A and IL-17F blockade, which could provide superior efficacy for some patients.
Market Penetration Factors
- Pricing flexibility: Biologic pricing strategies often involve rebates and discounts negotiated with payers.
- Biologic switching rates: Patients switch due to efficacy, safety, or convenience factors. The switching rate in psoriasis is approximately 15-20% annually (Sharma et al., 2021).
- Provider adoption: Influenced by clinical trial results, insurance coverage, and clinician familiarity.
Price Projections
Current Pricing Assumption
- Average wholesale price (AWP): Estimated at $4,000 per month per patient (based on analogous biologics)
- Annual treatment cost: Approximately $48,000 per patient
Revenue Projections
Year 1 (2023):
- Target market penetration: 0.5% (roughly 12,500 patients)
- Revenue estimate: 12,500 patients × $48,000 = $600 million
Year 3 (2025):
- Market penetration: 3% (75,000 patients)
- Revenue estimate: 75,000 × $48,000 = $3.6 billion
Year 5 (2027):
- Market penetration: 8% (200,000 patients)
- Revenue estimate: 200,000 × $48,000 = $9.6 billion
Pricing Dynamics
- Commercial payers might negotiate discounts ranging from 20-40%, reducing gross revenue accordingly.
- Biosimilar or shift to oral alternatives could pressure biologic prices downward after patent expiry (~2031).
Risks and Barriers
- Efficacy and safety concerns: Similar biologics faced safety scrutiny; adverse events could limit uptake.
- Patent litigations: Threats from biosimilar entrants post-2031.
- Market saturation: Existing biologics hold significant mindshare and insurance coverage.
Policy and Regulatory Influences
- The Inflation Reduction Act (2022) introduces discounts for Medicare—potentially impacting pricing strategies for biologics like Bimzelx.
- FDA's priority review and expedited pathways can accelerate access but don’t directly influence pricing.
Conclusion
Bimzelx's market potential hinges on clinical advantages and payer acceptance. Initial revenue estimates suggest a peak annual market near $10 billion, assuming aggressive adoption and price sustainability. Competitive pressure and payer negotiations will be primary determinants of actual revenue realization.
Key Takeaways
- Bimzelx targets a large, established biologics market with significant growth potential.
- Short-term revenues could reach $600 million in the first year; long-term projections exceed $9 billion annually.
- Pricing strategies will be critical, balancing competitive pricing with revenue goals amid payer pressure.
- Biosimilar competition post-2031 will impact long-term market share and pricing.
FAQs
1. How does Bimzelx differ from other IL-17 biologics?
It inhibits both IL-17A and IL-17F, potentially offering improved efficacy over drugs targeting only IL-17A.
2. What is the expected timeline for patient adoption?
Adoption likely begins in the second half of 2023, with steady growth over 2-3 years.
3. How will payer negotiations influence pricing?
Rebates and discounts negotiated with insurers can reduce effective prices by 20-40%.
4. What are the main barriers to market penetration?
Established competitor brands, safety concerns, and payer restrictions could slow adoption.
5. When is biosimilar competition expected?
Likely after patent expiry around 2031, which may lead to price erosion and market share redistribution.
References
[1] IMS Health. (2022). U.S. psoriasis patient population estimates.
[2] Sharma, P., et al. (2021). Biologic switching patterns in psoriasis. Journal of Dermatology.
[3] FDA. (2021). Bimzelx (bimekizumab) label and approval information.
[4] IQVIA Institute. (2022). Biologics market analysis.
[5] U.S. Inflation Reduction Act. (2022). Impact on drug pricing.
